Sugerencias
Idioma
metricas
Publique en esta revista
Guía para autores
Buscador
Información de la revista
Vol. 60. Núm. 3.
Páginas 161-238 (Julio - Septiembre 2025)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
5925
Vol. 60. Núm. 3.
Páginas 161-238 (Julio - Septiembre 2025)
Original article
Acceso a texto completo
Chloroquine and hydroxychloroquine induced cardiomyopathy: A systematic review of literature
Miocardiopatía inducida por cloroquina e hidroxicloroquina: una revisión sistemática de la literatura
Visitas
5925
Vanda Devesa Netoa,b,1,
Autor para correspondencia
vandadevesaneto@gmail.com

Corresponding author.
, João Gouveia Fiúzaa,1, Inês Piresa, Luís Ferreira Santosa, António Costaa
a Cardiology Department, Unidade Local de Saúde Viseu Dão-Lafões, Viseu, Portugal
b Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
fig0005
Tablas (1)
Table 1. Information about clinical cases included.
Tablas
Abstract
Introduction and objectives

Chloroquine (CQ) and hydroxychloroquine (HCQ), initially developed for malaria prophylaxis, are now widely used in rheumatic diseases, such as systemic lupus erythematosus and rheumatoid arthritis. Despite their therapeutic benefits, these drugs can induce cardiotoxicity, particularly cardiomyopathy. This systematic review evaluates the prevalence, clinical features, and diagnostic challenges of CQ/HCQ-induced cardiomyopathy.

Methods

A comprehensive literature search was conducted in PubMed, EMBASE, and Cochrane databases, identifying 60 studies reporting 79 cases of CQ/HCQ-induced cardiomyopathy. Inclusion criteria required histopathological confirmation via endomyocardial biopsy. Data on clinical presentations, diagnostic findings, and outcomes were extracted and analyzed.

Results

Patients were predominantly female (76%), with a median age of 56 years. The cardiomyopathies observed included hypertrophic, dilated, and restrictive forms, frequently presenting with heart failure and conduction disorders, such as atrioventricular block and arrhythmias. Cardiac magnetic resonance imaging and endomyocardial biopsy revealed characteristic toxicological changes, including myocyte vacuolization and fibrosis. Management often involved discontinuation of therapy, but severe cases progressed to cardiac transplantation or resulted in mortality (19%).

Conclusions

CQ/HCQ-induced cardiomyopathy is an underrecognized complication with significant morbidity and mortality. Early detection through continuous cardiac monitoring in patients on long-term CQ/HCQ therapy is crucial. Effective management, including timely drug discontinuation, may improve outcomes, although prognosis remains guarded in advanced stages.

Keywords:
Cardiomyopathy
Hydroxychloroquine
Toxicity
Abbreviations:
CQ
DCM
EMB
HCM
HCQ
RCM
Resumen
Introducción y objetivos

La cloroquina (CQ) y la hidroxicloroquina (HCQ), desarrolladas inicialmente para la profilaxis de la malaria, son hoy en día ampliamente utilizadas para el tratamiento de algunas enfermedades reumáticas, como el lupus eritematoso sistémico y la artritis reumatoide. A pesar de sus beneficios terapéuticos, estos fármacos pueden ocasionar toxicidad cardiovascular, concretamente cardiomiopatía. Esta revisión sistemática evalúa la prevalencia, las características clínicas y los retos diagnósticos de la cardiomiopatía inducida por CQ/HCQ.

Métodos

Se realizó una búsqueda exhaustiva en las bases de datos PubMed, EMBASE y Cochrane, identificando 60 estudios que comunican 79 casos de cardiomiopatía inducida por CQ/HCQ. Los criterios de inclusión requerían la confirmación histopatológica mediante biopsia endomiocárdica. Se extrajeron y analizaron datos sobre presentación clínica, hallazgos diagnósticos y resultados.

Resultados

Los pacientes fueron predominantemente mujeres (76%), con una edad media de 56 años. Las cardiomiopatías observadas incluyeron formas hipertróficas, dilatadas y restrictivas, que frecuentemente se presentaron con insuficiencia cardiaca y trastornos de la conducción, como bloqueo auriculoventricular y arritmias. La resonancia magnética cardiaca y la biopsia endomiocárdica revelaron cambios tóxicos característicos, como vacuolización de miocitos y fibrosis. El manejo generalmente requirió la suspensión del tratamiento, y algunos casos graves progresaron a trasplante cardiaco o resultaron en mortalidad (19%).

Conclusiones

La cardiomiopatía inducida por CQ/HCQ es una complicación infradiagnosticada con una morbimortalidad significativa. La detección precoz mediante seguimiento cardiológico cercano en pacientes que reciben tratamiento prolongado con CQ/HCQ es crucial. Un tratamiento efectivo, incluyendo la suspensión oportuna del fármaco, puede mejorar los resultados, aunque el pronóstico sigue siendo complejo en etapas avanzadas.

Palabras clave:
Miocardiopatía
Hidroxicloroquina
Toxicidad
Texto completo
Introduction

Chloroquine (CQ) was first discovered in 1934 and has been widely used for malaria prevention since World War II.1 A decade later, CQ and hydroxychloroquine (HCQ) were introduced for the treatment of rheumatic diseases and are now extensively used in managing conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other connective tissue disorders.2 Despite their therapeutic efficacy, both drugs have been increasingly associated with significant toxicities, particularly affecting the cardiovascular system.

HCQ differs structurally from CQ due to a hydroxyl group attached to the side chain's ethyl group, which contributes to its lower toxicity profile.1 Both medications are rapidly absorbed, with tissue concentrations reaching a steady state within 1–3 months (corresponding to five half-lives). Upon discontinuation, tissue concentrations decrease by 90–95% within 15 days.3,4 Although HCQ is considered to have a lower risk of toxicity, it has been implicated in a range of dose-dependent adverse effects, particularly when used in long-term therapy.1

Among the various toxicities, cardiac toxicity represents a serious and often underdiagnosed complication of long-term CQ and HCQ therapy. The primary mechanisms of cardiotoxicity involve lysosomal enzyme dysfunction, which leads to impaired degradation of intracellular materials and the accumulation of metabolic byproducts such as glycogen and phospholipids within cardiomyocytes.4,5 This disruption causes cellular vacuolization, hypertrophy, and fibrosis, culminating in cardiomyopathy and conduction disturbances.6

Cardiotoxicity from CQ/HCQ manifests as conduction disorders, including atrioventricular block (AVB), and progressive forms of cardiomyopathy that can lead to severe heart failure (HF). Despite the severe implications for morbidity and mortality, this form of cardiotoxicity remains underrecognized in clinical practice.6

Given the potential for severe cardiac complications, a comprehensive understanding of the toxicological mechanisms underlying CQ/HCQ-induced cardiotoxicity is essential for early detection and prevention. This review aims to explore the prevalence, clinical manifestations, diagnostic strategies, and management of CQ/HCQ-induced cardiomyopathy, with a focus on elucidating the toxicological pathways involved. By enhancing awareness and understanding of these complications, we can improve outcomes for patients undergoing long-term therapy with these drugs.

MethodsProtocol and literature search

We conducted a comprehensive literature search to investigate the association between CQ or HCQ and cardiomyopathy, particularly focusing on their toxicological effects on the cardiovascular system. The search, conducted via PubMed, EMBASE and Cochrane up to June 2024, employed a combination of keywords and Medical Subject Headings (MeSH) terms: “chloroquine” OR “hydroxychloroquine” AND “cardiomyopathy” OR “cardiomyopathies”. Our review follows PRISMA guidelines, ensuring transparency and reproducibility.

Eligibility criteria

Studies were included if they met the following criteria: (a) discussed the association between CQ or HCQ and cardiomyopathy and (b) confirmed the diagnosis of CQ/HCQ-induced cardiomyopathy through endomyocardial biopsy. Exclusion criteria included duplicate publications, unavailable full texts, studies unrelated to CQ/HCQ cardiotoxicity, or those not involving histopathological confirmation of cardiomyopathy.

Data collection and management

Two authors (V.D. Neto, J.G. Fiúza) independently screened all titles and abstracts for relevance, followed by a full-text review of eligible articles. Data on study populations, clinical characteristics, drug dosage, toxicological findings, and patient outcomes were extracted to ensure the inclusion of the most relevant and up-to-date information. Discrepancies in data extraction or study eligibility were resolved by discussion or consultation with a third reviewer. This process ensured consistency and accuracy across all reviewed studies.

Search results

Our search yielded 266 records. After screening the titles and abstracts, 199 articles were excluded for not meeting the inclusion criteria, leaving 67 for full-text review. A total of 60 articles were included in the final qualitative synthesis, documenting 79 cases of CQ/HCQ-induced cardiomyopathy. Cases are described in more detail in Table 1. Most studies were individual case reports or small case series, with no randomized controlled trials identified. A PRISMA flowchart (Fig. 1) details the selection process.

Table 1.

Information about clinical cases included.

Author  Year  Sex  Age  CQ/HCQ  Rheumatic disease  Duration  Cumulative dosage (g)  Presentation  Cardiac phenotype  Electrical disturbances  Outcome 
Schneider et al.7  2024  F  57  HCQ  MCDT  *  1238  *  *  *  Dead 
Schneider et al.7  2024  F  77  HCQ  SLE  *  1516.8  *  *  *  Dead 
Schneider et al.7  2024  F  63  HCQ  SLE  *  2558  *  *  *  *(Alive) 
Schneider et al.7  2024  F  69  HCQ  RA  *  1596.6  *  *  *  *(Alive) 
Schneider et al.7  2024  F  60  HCQ  RA  *  387.6  *  Hypertrophy  *  *(Alive) 
Schneider et al.7  2024  F  73  HCQ  Sjögren  *  3916.5  *  Hypertrophy  *  *(Alive) 
Schneider et al.7  2024  F  72  HCQ  SLE  *  428.6  *  Hypertrophy  *  *(Alive) 
Schneider et al.7  2024  F  62  HCQ  SLE  *  560.6  *  Hypertrophy  *  *(Alive) 
Schneider et al.7  2024  F  42  HCQ  SLE  *  767.2  *  *  *  Dead 
Schneider et al.7  2024  F  76  HCQ  Sjögren  *  776.4  *  *  *  *(Alive) 
Neto et al.8  2024  F  73  HCQ  SLE  13 years  1460  HF, syncope  Biventricular dysfunction  cAVB, FV  Dead 
Malhotra et al.9  2023  F  60  HCQ  RA  6 years  876  HF  DCM  LBBB  Good 
Braunstein et al.10  2022  F  69  HCQ  *  *  *  HF  Biventricular dysfunction  VT  * 
Ramahi et al.11  2022  F  41  HCQ  SLE  2 years  219  HF  DCM  Prolonged QT  Good 
Naddaf et al.12  2021  F  69  HCQ  *  *  *  *  Hypertrophic  Prolonged QT  Unknown 
Lodge et al.13  2021  F  51  HCQ  SLE  19 years  2774  Syncope  Restrictive  RBBB  Good 
Ezzeddine et al.14  2021  F  60  HCQ  SLE  30 years  2190  HF  Hypertrophic  SSS, Afib  Good 
Nadeem et al.15  2021  F  60  HCQ  Scleroderma  20 years  2920  HF  Biventricular dysfunction  cAVB  Cardiac transplant 
Wakfie-Corieh et al.16  2021  F  61  CQ  RA  10 years  *  HF  Hypertrophic  *  * 
Hanneman et al.17  2020  F  68  *  *  *  *  *  *  *  * 
Santana et al.18  2020  F  51  HCQ  SLE  10 years  1460  HF  DCM  1st degree AVB  Progressive HF symptoms 
Abbi et al.19  2020  F  42  HCQ  SLE  10 years  1460  HF  DCM  *  * 
Muthukumar et al.20  2020  F  59  HCQ  RA  23 years  5037  HF  DCM  1st degree AVB  Heart transplantation 
Layoun et al.21  2020  F  70  HCQ  RA  *  *  cAVB  DCM  cAVB  Good 
Alder et al.22  2020  F  51  CQ  MCDT  10 years  730  Cardiogenic shock  Biventricular dysfunction  AVB  Dead 
Chang et al.23  2019  F  63  HCQ  SLE  20 years  2190  HF  Hypertrophic  Sinus bradicardia  Progressive HF symptoms 
Girolamo et al.24  2018  Male  60  HCQ  RA  27 months  324  HF  DCM  *  Good 
Zhao et al.25  2018  F  55  HCQ  SLE  10 years  1460  HF  DCM  *  Good 
Zhao et al.25  2018  F  48  HCQ  SLE  Unknown  *  HF  DCM  *  Dead 
Girolamo et al.24  2018  F  41  HCQ  SLE  3 months  *  HF  DCM  *  Progressive HF symptoms 
Dogar et al.26  2018  Male  60  HCQ  RA  Unknown  *  HF  Preserved EF  *  Progressive HF symptoms 
Yogasundaram et al.27  2018  F  45  CQ  RA  20 years  1825  HF  Restrictive  Bifascicular block  Good 
Sabato et al.28  2017  F  75  HCQ  SLE  11 years  1606  HF  Restrictive  Sinus bradicardia  Good 
Tselios et al.29  2016  F  74  HCQ  SLE  13 years  1623  HF  DCM  Good   
Chatre et al.30  2016  F  61  HCQ  SLE  17 years  2480  Stroke  Hypertrophy  *  Myocardial infarction, stroke 
Abdin et al.31  2016  F  58  HCQ  Sjögren  2 years  292  HF  DCM  cAVB  Dead 
Pavsic et al.32  2016  F  76  CQ  Sjögren  6 years  547.5  HF  Restrictive  cAVB 4 years before  Good 
Yogasundaram et al.33  2014  F  59  HCQ  RA  >14 years  >1020  HF  Restrictive  RBBB  Dead 
Lopez-Ruiz et al.34  2014  F  36  CQ  SLE  14 years  1278  Syncope  Hypertrophy  cAVB  Good 
Joyce et al.35  2013  F  52  HCQ  RA  8 years  1168  HF  DCM  LBBB  Dead 
Vereckei et al.36  2013  F  56  CQ  Unknown  2 years  1825  Dizziness  Restrictive  cAVB, prolonged QT  Good 
Bae et al.37  2012  F  63  HCQ  RA  2 years  164  cAVB  DCM  cAVB  Good 
Frustaci et al.38  2012  Male  39  HCQ  DLE  *  164  HF  Restrictive  cAVB  Good 
Abbasi et al.39  2012  F  52  HCQ  SLE  15 years  *  HF  DCM  *  Good 
Azimian et al.40  2012  F  64  HCQ  RA  20 years  2920  HF  Restrictive  Afib/SSS  Dead 
TÖNNESMANN et al.41  2012  F  65  CQ  RA  35 years  3195  Syncope  Hypertrophy  cAVB  Good 
Azimian et al.40  2012  F  38  CQ  SLE  7 years  1277.5  Syncope  DCM  High-grade AVB  Dead 
Newton-Cheh et al.42  2011  Male  47  HCQ  SLE  14 years  2191  HF, syncope  Restrictive  cAVB  good 
Hartmann et al.43  2011  F  75  HCQ  RA  10 years  *  HF  DCM  LBBB  Good 
Muthukrishnan et al.44  2011  F  66  HCQ  SLE  24 years  3504  HF  DCM  cAVB  Dead 
Cervera et al.45  2011  F  64  CQ  SLE  7 years  1000  HF  DCM  cAVC 1 year before  Good 
Pieroni et al.46  2011  F  59  CQ  MCDT  5 years  1095  HF  DCM  *  * 
Lee et al.47  2010  F  52  HCQ  RA  12 years  1898  Syncope  DCM  SSS  Good 
Manohar et al.48  2009  F  64  HCQ  SLE  10 years  *  HF  Restrictive  Unknown  Good 
Fragasso et al.49  2009  F  64  HCQ  *  10 years  *  HF  DCM  RBBB  Good 
Soong et al.50  2007  F  55  HCQ  SLE  10 years  1460  HF  DCM  *  Dead 
Soong et al.50  2007  F  65  HCQ  Scleroderma  25 years  3650  HF  Restrictive  2nd degree AVB  Good 
Costedoat-Chalumeau et al.51  2006  F  59  CQ/HCQ  DLE  13 years  680/580  HF  DCM  cAVB  Heart transplantation 
Reffelmann et al.52  2006  F  67  CQ  RA  20 years  1825  HF  Restrictive  RBBB  Good 
Keating et al.53  2005  F  39  HCQ  SLE  4 years  580  Syncope  DCM  1st degree AV block  Unknown 
Cotroneo et al.54  2005  F  51  HCQ  SLE  35 years  5110  HF  DCM  RBBB  Good 
Naqvi et al.55  2005  F  61  CQ  SLE  29 years  2300  cAVB, HF  Hypertrophic  cAVB  Good 
Nord et al.56  2004  F  31  HCQ  SLE  12 years  1750  HF  DCM  *  Dead 
Freihage et al.57  2004  F  50  CQ  RA  6 years  1096  HF, syncope  Restrictive  cAVB  Heart transplantation 
Roos et al.58  2002  F  73  HCQ  RA  2 years  1461  HF  *  *  Dead 
Roos et al.58  2002  Male  53  HCQ  RA  *  *  HF  *  *  * 
Teixeira et al.59  2002  F  58  CQ  RA  9 years  822  Syncope  Hypertrophy  cAVB  Good 
Roos et al.58  2002  F  67  CQ  SLE  2 years  183  HF  *  Afib  Dead 
Baguet et al.60  1999  F  58  CQ/HCQ  SLE  25 years  637/4830  HF  Hypertrophy  RBBB  Good 
Venoit et al.61  1998  F  60  CQ  RA  10 years  910  *  *  *  Dead 
August et al.62  1994  F  81  *  *  25 years  4562.5  HF  Hypertrophic  cAVB  Dead 
Iglesias-Cubero et al.63  1993  F  59  CQ  DLE  25 years  2280  HF  Hypertrophy  cAVB  Dead 
Estes et al.64  1987  F  58  HCQ/CQ  DLE  16 years  731  *  DCM  cAVB  Good 
Ratliff et al.65  1987  F  59  HCQ  SLE  2 years  292  HF  *  *  Good 
Ratliff et al.65  1987  F  58  HCQ  DLE  6 years  438  HF  Restrictive  cAVB  Good 
Estes et al.64  1987  Male  59  CQ  SLE  2 years  292  *  *  *  * 
McAllister et al.66  1987  F  73  CQ  SLE  8 years  730  *  *  *  Death 
McAllister et al.66  1987  F  33  CQ  SLE  11 years  1005  *  Hypertrophy  *  * 
Magnussen et al.67  1977  F  35  CQ  Psoriasis  7 years  2555  HF  *  RBBB  Good 

Afib, atrial fibrillation; AVB, atrioventricular block; cAVB, complete atrioventricular block; CQ, chloroquine; DCM, dilated cardiomyopathy; DLE, discoid lupus erythematosus; F, female; HCQ, hydroxychloroquine; HF, heart failure; LBBB, left bundle branch block; MCDT, mixed connection tissue disorder; RA, rheumatoid arthritis; RBBB, right bundle branch block; SLE, systemic lupus erythematosus; SSS, sick sinus syndrome.

*

Unknown information.

Fig. 1.

PRISMA flowchart.

Study characteristics and demographics

Most patients were female (n=76%), with a median age of 60 years (range: 35–81 years). This demographic is reflective of the higher prevalence of autoimmune diseases, such as SLE and RA, among women.

SLE was the most common underlying condition, present in 51% of cases (n=40), followed by RA in 25% of cases (n=20). Other conditions included Sjögren's syndrome (n=9, 11%) and mixed connective tissue disease (n=5, 6%).

Duration and cumulative dosage of therapy

The duration of CQ/HCQ therapy varied significantly across patients, ranging from 2 months to over 35 years (median duration: 10 years). The cumulative dosages ranged from 164g to 5110g, with a median cumulative dose of 1825g. Prolonged exposure and higher cumulative doses were associated with increased risk of cardiotoxicity, particularly in cases with durations exceeding 10 years of continuous therapy.

Cardiac manifestations: cardiomyopathy

HF was the predominant clinical presentation, occurring in 62% of patients (n=49). HCQ-induced cardiomyopathy is predominantly described as hypertrophic cardiomyopathy (HCM); however, cases of dilated (DCM) and restrictive cardiomyopathy (RCM) have also been reported.

Concentric hypertrophy was the most frequently observed cardiac phenotype, present in 45% of cases (n=36). For cases with available data (n=13), the median cumulative dosage was 2190g (range: 387.6–3916.5g), with a median exposure duration of 20 years (range: 9–35 years).

The second most common phenotype was DCM identified in 35% of cases (n=28). For the cases with reported data (n=24), the median cumulative dosage was 1368.8g (range: 164–5110g), and the median exposure duration was 10 years (range: 0.25–35 years).

The least frequent phenotype was RCM, observed in 20% of cases (n=16). For the cases with dosage and duration data (n=12), the median cumulative dosage was 1825g (range 164–3650g), and the median exposure duration was 14 years (range 2–25 years).

HCM was the most common phenotype with apparently shorter therapy durations and a broader dosage range, indicating greater variability in the factors contributing to its development. HCM occurred after longer therapy durations (median 20 years) and moderately high cumulative dosages, suggesting that prolonged exposure may be a critical factor in its pathogenesis. RCM was intermediate between HCM and DCM in both therapy duration and cumulative dosage. This suggests that RCM might develop after prolonged therapy but potentially less so than HCM.

Patients with HCM had features comparable to those observed in other lysosomal storage disorders, such as Anderson-Fabry and Danon disease, which share a similar pathophysiology involving lysosomal dysfunction and intracellular storage of metabolic products.68,69

Hydroxychloroquine toxicity may lead to false-positive results in cardiac scintigraphy using bisphosphonates, potentially resulting in a misdiagnosis of cardiac amyloidosis. In such cases, endomyocardial biopsy plays a crucial role in confirming the diagnosis.16

Conduction disturbances

Conduction abnormalities were present in 40% of cases (n=32), with the most common disturbances being AVB. Specifically, third-degree AVB occurred in 15% of cases (n=12), often requiring permanent pacemaker implantation. QT prolongation was identified in 10% of cases (n=8), which in some instances led to Torsades de Pointes and ventricular tachycardia, requiring implantable cardioverter-defibrillator placement.8,10

Cardiac magnetic resonance imaging (CMR)

CMR has been instrumental in diagnosing and characterizing the extent of cardiomyopathy in patients with CQ HCQ-induced cardiomyopathy. Common findings include late gadolinium enhancement (LGE), indicative of myocardial fibrosis, and low native T1 mapping values, reflecting lipid overload associated with the lysosomal storage nature of the disease. However, in some cases, prolonged exposure to HCQ may lead to diffuse myocardial fibrosis and edema, resulting in strikingly increased native T1 values. This is likely due to the progression of the pathological process from glycosphingolipid accumulation to fibrosis and inflammation, as indicated by increased T1 and T2 values.7,8,15,33,70

The CMR findings in HCQ-induced cardiomyopathy closely resemble those observed in Anderson-Fabry disease (AFD), making differential diagnosis challenging. In such cases, additional diagnostic methods, such as genetic testing and endomyocardial biopsy, may be necessary to confirm the diagnosis.15,33,70

Both HCQ-induced cardiomyopathy and Anderson-Fabry disease often present with decreased T1 mapping values due to lipid or lysosomal product accumulation. However, in AFD, T1 values are typically markedly reduced (e.g., often below 900ms on 1.5T scanners), which can help differentiate the two conditions. In Danon disease, T1 values do not follow a consistent pattern but are often elevated due to extensive myocardial fibrosis.15,33,70

The patterns of LGE also vary between these conditions:

  • -

    HCQ-induced cardiomyopathy: Patchy, mid-myocardial, or subepicardial enhancement, consistent with non-ischemic fibrosis.

  • -

    Anderson-Fabry disease: LGE commonly involves the basal inferolateral wall of the left ventricle.

  • -

    Danon disease: LGE is often diffuse with extensive myocardial involvement, though typically non-specific. 15,33,70 T2 mapping may reveal subtle increases in HCQ-induced cardiomyopathy, reflecting inflammation or edema. Active Danon disease frequently exhibits higher T2 values due to pronounced inflammation. In contrast, early-stage Anderson-Fabry disease typically presents with normal T2 values, with elevations observed only in advanced stages of the disease.15,33,70

Endomyocardial biopsy

Endomyocardial biopsy (EMB) remains the definitive diagnostic tool for HCQ-induced cardiomyopathy, particularly in distinguishing it from other forms of cardiomyopathy and cardiac manifestations of connective tissue diseases.

Lysosomal storage disorders, including HCQ-induced cardiomyopathy, involve the accumulation of substances within lysosomes, leading to hypertrophy and vacuolization in cardiomyocytes. Myocyte vacuolization is a hallmark of drug-induced lysosomal storage disease. Focal interstitial fibrosis and myocyte hypertrophy further contribute to cardiac dysfunction.7–67

Although vacuolated cardiomyocytes visible under light microscopy are strongly suggestive of lysosomal storage disease, they are not specific to HCQ-induced cardiomyopathy and may also be seen in Anderson-Fabry and Danon diseases. Histological differences, such as the absence of periodic acid-Schiff (PAS) positivity in HCQ-induced cases, can help exclude glycogen storage disorders.7–67

Electron microscopy is considered necessary to confirm HCQ-induced cardiomyopathy when light microscopy findings are inconclusive. The presence of curvilinear bodies in biopsy specimens is pathognomonic for HCQ-induced cardiomyopathy, distinguishing it from Anderson-Fabry (characterized by globotriaosylceramide accumulation) and Danon disease.33 However, when electron microscopy is unavailable, clinical judgment and light microscopy findings may suffice for diagnosis in appropriate scenarios.8

Outcomes and prognosis

HCQ-induced cardiomyopathy may show partial or complete reversibility after discontinuing the drug. This reversibility appears to depend on the severity of myocardial involvement and how early the condition is detected and treated. However, in cases of advanced cardiomyopathy with significant fibrosis, the damage may be irreversible, as fibrotic tissue does not recover.33

Despite discontinuation of CQ/HCQ therapy in most cases, the outcomes varied widely. Cardiac transplantation was required in 5% of cases (n=4), reflecting the severity of left ventricular dysfunction in certain patients.15,20,21 Mortality rate was 19% (n=15), with most deaths occurring within 1 year of diagnosis despite cessation of CQ/HCQ and initiation of aggressive HF treatment7,8,22,25,31 and 40% of patients (n=32) showed clinical improvement following cessation of therapy and appropriate heart failure management.

Discussion

This systematic review highlights the significant risk of HCQ and CQ-induced cardiomyopathy in patients undergoing long-term treatment, particularly for SLE and RA. Our findings, drawn from 79 individual cases, reveal that both drugs can cause severe cardiac toxicity, manifesting as hypertrophic, dilated, and restrictive cardiomyopathies. While HCQ is generally regarded as having a more favorable safety profile compared to CQ, our review demonstrates that both drugs can lead to severe cardiac events, particularly after prolonged exposure or at high cumulative doses.1,3

HCQ and CQ belong to the category of cationic amphiphilic drugs, which preferentially bind to phospholipids and accumulate in lysosomes.3 This accumulation disrupts normal lysosomal function, leading to a rise in lysosomal pH and subsequent inhibition of lysosomal enzymes such as alpha- and beta-galactosidase. This enzyme inhibition impairs intracellular degradation and causes the accumulation of phospholipids and glycogen, mimicking the pathophysiology of lysosomal storage diseases.70,71 As these metabolic products accumulate within the cardiac myocytes, they result in vacuolated cytoplasm, myocyte hypertrophy, and eventually myocardial fibrosis.72

Patients has frequently associated diastolic dysfunction, and in many cases, the histopathological findings resembled those of genetic lysosomal storage disorders such as Anderson-Fabry and Danon diseases.68,69 This suggests that the lysosomal dysfunction caused by HCQ and CQ shares common pathways with these genetic conditions.

The accumulation of metabolic products also affects the cardiac conduction system, leading to a range of conduction disturbances. These conduction abnormalities often manifested as bradyarrhythmia requiring permanent pacemaker implantation or as life-threatening tachyarrhythmias, such as ventricular tachycardia, requiring implantable cardioverter-defibrillator placement.8,10,21,31,32

Although conduction disturbances are frequently associated with connective tissue disorders, such as SLE, the occurrence of third-degree AVB and Torsades de Pointes in this population is relatively rare, further suggesting a drug-specific toxicity mechanism. This underscores the importance of monitoring for electrical disturbances in patients on long-term HCQ or CQ therapy.73

CMR proved to be a critical diagnostic tool in detecting the structural changes associated with HCQ/CQ cardiomyopathy. Late gadolinium enhancement and low T1 mapping, indicative of myocardial fibrosis and lipid overload, were common findings.33,70 These CMR features closely resemble those seen in Anderson-Fabry cardiomyopathy, further complicating the differential diagnosis between these conditions. In such cases, additional diagnostic methods, such as EMB and genetic testing, are necessary to confirm the diagnosis and rule out other storage diseases.70

EMB is widely regarded as the key for diagnosing HCQ/CQ-induced cardiomyopathy, particularly when the clinical presentation and imaging findings are insufficient for a definitive diagnosis.15,74 The most common histopathological findings in the cases we reviewed included myocyte vacuolization, focal interstitial fibrosis, and myocyte hypertrophy, all of which are indicative of lysosomal storage dysfunction.7–67 The presence of myeloid bodies and curvilinear inclusions under electron microscopy was crucial in distinguishing HCQ/CQ cardiomyopathy from other lysosomal storage disorders.33,70

Despite discontinuing HCQ/CQ therapy, many patients in this review experienced persistent or progressive cardiac dysfunction, with 19% (n=15) of cases resulting in death. Notably, cardiac transplantation was required in 5% of cases (n=4), underscoring the severity of HCQ/CQ-induced cardiomyopathy.15,20,21 The findings emphasize the need for early recognition of cardiotoxicity and the importance of regular cardiac monitoring in patients on long-term therapy. The relatively high mortality rate associated with these cases highlights the necessity of discontinuing the medication as soon as cardiotoxicity is suspected and implementing aggressive heart failure management to prevent further progression.7,8,22,25,31

This review has several limitations. The majority of included studies were case reports or small case series, which inherently limits the generalizability of the findings. Additionally, there was variability in the diagnostic criteria used across studies, particularly in the use of CMR vs EMB for diagnosis. Finally, the lack of randomized controlled trials examining HCQ/CQ-induced cardiotoxicity limits the ability to establish definitive causal relationships between drug exposure and cardiac outcomes. Future studies should aim to provide more robust, controlled data on the cardiotoxic effects of these medications, particularly in relation to dose-response relationships and the long-term prognosis of affected patients.

Conclusions

CQ and HCQ-induced cardiomyopathy is an underrecognized but significant complication of long-term therapy, particularly in patients with SLE and RA. Our systematic review highlights the diverse clinical manifestations, ranging from hypertrophic, dilated, and restrictive cardiomyopathies to conduction disturbances, often leading to severe morbidity and mortality. Early identification through routine cardiac monitoring, including cardiac imaging and, when indicated, EMB, is crucial for timely diagnosis and intervention. Discontinuation of the offending drug may lead to clinical improvement, but in advanced cases, irreversible myocardial damage necessitates HF management or even cardiac transplantation. Given the potential severity of this condition, increased awareness among clinicians is essential to improve patient outcomes and guide future research on preventive strategies.

Funding

The authors have no funding to declare.

Ethical considerations

As this is a systematic review based on previously published studies, no ethical approval or participant consent was required. The authors adhered to the SAGER (Sex and Gender Equity in Research) guidelines to address potential sex and gender considerations in the reviewed literature.

Statement on the use of artificial intelligence

During the preparation of this work, the authors used OpenAI's ChatGPT for assistance in revising and refining text. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

Authors’ contributions

V.D. Neto and J.G. Fiúza: conceptualization, methodology, data collection, analysis, writing (original draft preparation), and supervision. I. Pires: data collection, manuscript formatting, and writing (review and editing). L. Ferreira Santos: critical review of the manuscript, visualization, and final approval of the version to be submitted. A. Costa: supervision, critical revisions, and final approval of the manuscript.

Conflicts of interest

The authors have nothing to declare.

References
[1]
M. Qozi, F.L. Cantrell.
Chloroquine/hydroxychloroquine.
Encyclopedia of Toxicology, 3rd ed., pp. 913-915
[2]
A. Fanouriakis, M. Kostopoulou, J. Andersen, et al.
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Ann Rheum Dis, 83 (2024), pp. 15-29
[3]
S. De Gregori, F. Falaschi, A. Ballesio, et al.
Hydroxychloroquine blood concentrations can be clinically relevant also after drug discontinuation.
Drugs R D, 22 (2022), pp. 155-163
[4]
A.H. Mackenzie.
Pharmacologic actions of 4-aminoquinoline compounds.
[5]
E.L. Nirk, F. Reggiori, M. Mauthe.
Hydroxychloroquine in rheumatic autoimmune disorders and beyond.
EMBO Mol Med, 12 (2020), pp. e12476
[6]
C. Chatre, F. Roubille, H. Vernhet, et al.
Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature.
Drug Saf, 41 (2018), pp. 919-931
[7]
A. Schneider, J. Sadhana, M.D. Menindez, et al.
Hydroxychloroquine induced cardiotoxicity: a case series.
Rom J Intern Med, 62 (2024), pp. 210-215
[8]
V. Devesa Neto, J. Fiúza, I. Pires, et al.
Hydroxychloroquine-induced cardiomyopathy predominantly affecting the right ventricle.
Eur Heart J Cardiovasc Imaging, 25 (2024), pp. e141
[9]
A. Malhotra, M.A. Pathak, T. Dalia, et al.
Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis.
BMJ Case Rep, 16 (2023), pp. e252327
[10]
E.D. Braunstein, D.S. Olshan, J.K. Gabriels, et al.
Hydroxychloroquine-associated cardiomyopathy with midmyocardial right ventricular tachycardia.
JACC Clin Electrophysiol, 8 (2022), pp. 1467-1469
[11]
A. Ramahi, A. Heider, J.M. Kahlenberg.
Rapid onset and resolution of hydroxychloroquine cardiomyopathy: a case report.
Case Rep Rheumatol, 2022 (2022), pp. 6503453
[12]
E. Naddaf, P. Paul, O.F. AbouEzzeddine.
Chloroquine and hydroxychloroquine myopathy: clinical spectrum and treatment outcomes.
Front Neurol, 11 (2021), pp. 616075
[13]
F.M. Lodge, W.E. Moody, S. Tosounidou, et al.
Hydroxychloroquine-induced cardiomyopathy accelerated after gastric banding.
[14]
F.M. Ezzeddine, J.R. Giudicessi, J.J. Maleszewski, et al.
Unmasking hydroxychloroquine cardiotoxicity in a patient with heart failure and chronotropic incompetence.
JACC Case Rep, 3 (2021), pp. 997-1001
[15]
U. Nadeem, M. Raafey, G. Kim, et al.
Chloroquine- and hydroxychloroquine-induced cardiomyopathy: a case report and brief literature review.
Am J Clin Pathol, 155 (2021), pp. 793-801
[16]
C.G. Wakfie-Corieh, N. Ramos López, M. Saiz-Pardo Sanz, et al.
Not all heart uptakes on 99mTc-DPD scintigraphy are amyloidosis: chloroquine-induced cardiomyopathy.
Clin Nucl Med, 46 (2021), pp. e188-e189
[17]
K. Hanneman, H.V. Alberdi, G.R. Karur, et al.
Antimalarial-induced cardiomyopathy resembles Fabry disease on cardiac MRI.
JACC Cardiovasc Imaging, 13 (2020), pp. 879-881
[18]
H. Matos Santana, B. Heindl, S. Suri, et al.
A case of heart failure in a patient with systemic lupus erythematosus.
JACC Case Rep, 2 (2020), pp. 414-419
[19]
B. Abbi, S. Patel, A. Kumthekar, et al.
A case of cardiomyopathy with long-term hydroxychloroquine use.
J Clin Rheumatol, 26 (2020), pp. e300
[20]
L. Muthukumar, A. Jahangir, M.F. Jan, et al.
Double jeopardy cardiomyopathy requiring heart transplant: hydroxychloroquine and rheumatoid arthritis.
[21]
M.E. Layoun, J. Desmarais, S.B. Heitner, et al.
Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy.
Eur Heart J, 41 (2020), pp. 2414
[22]
M. Alder, R. Gupta, G.E. Davogustto, et al.
Chloroquine cardiotoxicity leading to cardiogenic shock.
JACC Case Rep, 2 (2020), pp. 2381-2386
[23]
A. Chang, G. Stolin, J. Fan, et al.
Hypertrophic cardiomyopathy in a lupus patient: a case of hydroxychloroquine cardiotoxicity.
ESC Heart Fail, 6 (2019), pp. 1326-1330
[24]
F. Di Girolamo, E. Claver, M. Olivé, et al.
Dilated cardiomyopathy and hydroxychloroquine-induced phospholipidosis: from curvilinear bodies to clinical suspicion.
Rev Esp Cardiol, 71 (2018), pp. 491-493
[25]
H. Zhao, J. Wald, M. Palmer, et al.
Hydroxychloroquine-induced cardiomyopathy and heart failure in twins.
J Thorac Dis, 10 (2018), pp. E70-E73
[26]
M.U. Dogar, N.N. Shah, S. Ishtiaq, et al.
Hydroxychloroquine-induced restrictive cardiomyopathy: a case report.
Postgrad Med J, 94 (2018), pp. 185-186
[27]
H. Yogasundaram, W. Hung, I.D. Paterson, et al.
Chloroquine-induced cardiomyopathy: a reversible cause of heart failure.
ESC Heart Fail, 5 (2018), pp. 372-375
[28]
L.A. Sabato, L.A. Mendes, Z.L. Cox.
Restrictive cardiomyopathy associated with long-term use of hydroxychloroquine for systemic lupus erythematosus.
J Pharm Pract, 30 (2017), pp. 571-575
[29]
K. Tselios, D.D. Gladman, P. Harvey, et al.
Hydroxychloroquine-induced cardiomyopathy in systemic lupus erythematosus.
J Clin Rheumatol, 22 (2016), pp. 287-288
[30]
C. Chatre, N. Filippi, F. Roubille, et al.
Heart Involvement in a woman treated with hydroxychloroquine for systemic lupus erythematosus revealing Fabry disease.
J Rheumatol, 43 (2016), pp. 997-998
[31]
A. Abdin, J. Pöss, R. Kandolf, et al.
Hydroxychloroquine-induced cardiomyopathy in a patient with limited cutaneous systemic sclerosis.
Clin Res Cardiol, 106 (2017), pp. 234-236
[32]
N. Pavsic, J. Mraz, Z.D. Strazar, et al.
Shunt reversal due to deterioration of chloroquine-induced cardiomyopathy in a patient with primary Sjögren syndrome.
Int J Cardiol, 215 (2016), pp. 145-146
[33]
H. Yogasundaram, B.N. Putko, J. Tien, et al.
Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment.
Can J Cardiol, 30 (2014), pp. 1706-1715
[34]
N. Lopez-Ruiz, C.E. Uribe.
Chloroquine cardiomyopathy: beyond ocular adverse effects.
BMJ Case Rep, 2014 (2014),
[35]
E. Joyce, A. Fabre, N. Mahon.
Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review.
Eur Heart J Acute Cardiovasc Care, 2 (2013), pp. 77-83
[36]
A. Vereckei, A. Fazakas, T. Baló, et al.
Chloroquine cardiotoxicity mimicking connective tissue disease heart involvement.
Immunopharmacol Immunotoxicol, 35 (2013), pp. 304-306
[37]
S.M. Bae, H.O. Jung, S.M. Ihm, et al.
Hydroxychloroquine-induced cardiomyopathy that presented as pulmonary hypertension: a newly noted complication.
Cardiology, 123 (2012), pp. 197-200
[38]
A. Frustaci, E. Morgante, D. Antuzzi, et al.
Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy.
Int J Cardiol, 157 (2012), pp. 117-119
[39]
S. Abbasi, L. Tarter, R. Farzaneh-Far, et al.
Hydroxychloroquine: a treatable cause of cardiomyopathy.
J Am Coll Cardiol, 60 (2012), pp. 786
[40]
M. Azimian, S.H. Gultekin, J.L. Hata, et al.
Fatal antimalarial-induced cardiomyopathy: report of 2 cases.
J Clin Rheumatol, 18 (2012), pp. 363-366
[41]
E. Tönnesmann, I. Stroehmann, R. Kandolf, et al.
Cardiomyopathy caused by long-term treatment with chloroquine: a rare disease, or a rare diagnosis?.
J Rheumatol, 39 (2012), pp. 1099-1103
[42]
C. Newton-Cheh, A.E. Lin, A.L. Baggish, et al.
Case records of the Massachusetts General Hospital Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure.
N Engl J Med, 364 (2011), pp. 1450-1460
[43]
M. Hartmann, I.L. Meek, G.K. van Houwelingen, et al.
Acute left ventricular failure in a patient with hydroxychloroquine-induced cardiomyopathy.
Neth Heart J, 19 (2011), pp. 482-485
[44]
P. Muthukrishnan, H. Roukoz, G. Grafton, et al.
Hydroxychloroquine-induced cardiomyopathy: a case report.
[45]
A. Cervera, G. Espinosa, J. Font, et al.
Cardiac toxicity secondary to long-term treatment with chloroquine.
Ann Rheum Dis, 60 (2001), pp. 301
[46]
M. Pieroni, C. Smaldone, A. Camporeale, et al.
Chloroquine-induced transition from dilated to restrictive cardiomyopathy.
J Am Coll Cardiol, 57 (2011), pp. 515
[47]
J.H. Lee, W.B. Chung, J.H. Kang, et al.
A case of chloroquine-induced cardiomyopathy that presented as sick sinus syndrome.
Korean Circ J, 40 (2010), pp. 604-608
[48]
V.A. Manohar, K.G. Moder, W.D. Edwards, et al.
Restrictive cardiomyopathy secondary to hydroxychloroquine therapy.
J Rheumatol, 36 (2009), pp. 440-441
[49]
G. Fragasso, F. Sanvito, F. Baratto, et al.
Cardiotoxicity after low-dose chloroquine antimalarial therapy.
Heart Vessels, 24 (2009), pp. 385-387
[50]
T.R. Soong, L.A. Barouch, H.C. Champion, et al.
New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy: a report of 2 cases.
Hum Pathol, 38 (2007), pp. 1858-1863
[51]
N. Costedoat-Chalumeau, J.S. Hulot, Z. Amoura, et al.
Cardiomyopathy related to antimalarial therapy with illustrative case report.
Cardiology, 107 (2007), pp. 73-80
[52]
T. Reffelmann, A. Naami, E. Spuentrup, et al.
Contrast-enhanced magnetic resonance imaging of a patient with chloroquine-induced cardiomyopathy confirmed by endomyocardial biopsy.
Circulation, 114 (2006), pp. e357-e358
[53]
R.J. Keating, S. Bhatia, S. Amin, et al.
Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction.
J Am Soc Echocardiogr, 18 (2005), pp. 981
[54]
J. Cotroneo, K.M. Sleik, E.R. Rodriguez, et al.
Hydroxychloroquine-induced restrictive cardiomyopathy.
Eur J Echocardiogr, 8 (2007), pp. 247-251
[55]
T.Z. Naqvi, D. Luthringer, A. Marchevsky, et al.
Chloroquine-induced cardiomyopathy: echocardiographic features.
J Am Soc Echocardiogr, 18 (2005), pp. 383-387
[56]
J.E. Nord, P.K. Shah, R.Z. Rinaldi, et al.
Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature.
Semin Arthritis Rheum, 33 (2004), pp. 336-351
[57]
J.H. Freihage, N.C. Patel, W.R. Jacobs, et al.
Heart transplantation in a patient with chloroquine-induced cardiomyopathy.
J Heart Lung Transplant, 23 (2004), pp. 252-255
[58]
J.M. Roos, M.C. Aubry, W.D. Edwards.
Chloroquine cardiotoxicity: clinicopathologic features in three patients and comparison with three patients with Fabry disease.
Cardiovasc Pathol, 11 (2002), pp. 277-283
[59]
R.A. Teixeira, M. Martinelli Filho, L.A. Benvenuti, et al.
Cardiac damage from chronic use of chloroquine: a case report and review of the literature.
Arq Bras Cardiol, 79 (2002), pp. 85-88
[60]
J.P. Baguet, F. Tremel, M. Fabre.
Chloroquine cardiomyopathy with conduction disorders.
Heart, 81 (1999), pp. 221-223
[61]
J.P. Veinot, K.T. Mai, R. Zarychanski.
Chloroquine-related cardiac toxicity.
J Rheumatol, 25 (1998), pp. 1221-1225
[62]
C. August, H.J. Holzhausen, A. Schmoldt, et al.
Histological and ultrastructural findings in chloroquine-induced cardiomyopathy.
J Mol Med (Berl), 73 (1995), pp. 73-77
[63]
G. Iglesias Cubero, J.J. Rodriguez Reguero, J.M. Rojo Ortega.
Restrictive cardiomyopathy caused by chloroquine.
Br Heart J, 69 (1993), pp. 451-452
[64]
M.L. Estes, D. Ewing-Wilson, S.M. Chou, et al.
Chloroquine neuromyotoxicity: clinical and pathologic perspective.
Am J Med, 82 (1987), pp. 447-455
[65]
N.B. Ratliff, M.L. Estes, J.L. Myles, et al.
Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy.
N Engl J Med, 316 (1987), pp. 191-193
[66]
H.A. McAllister Jr., V.J. Ferrans, R.J. Hall, et al.
Chloroquine-induced cardiomyopathy.
Arch Pathol Lab Med, 111 (1987), pp. 953-956
[67]
I. Magnussen, B. de Fine Olivarius.
Cardiomyopathy after chloroquine treatment.
Acta Med Scand, 202 (1977), pp. 429-431
[68]
B.N. Putko, K. Wen, R.B. Thompson, et al.
Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.
Heart Fail Rev, 20 (2015), pp. 179-191
[69]
I. Nishino, J. Fu, K. Tanji, et al.
Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease).
Nature, 406 (2000), pp. 906-910
[70]
E. Tönnesmann, R. Kandolf, T. Lewalter.
Chloroquine cardiomyopathy: a review of the literature.
Immunopharmacol Immunotoxicol, 35 (2013), pp. 434-442
[71]
A. Frustaci, E. Morgante, D. Antuzzi, et al.
Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy.
Int J Cardiol, 157 (2012), pp. 117-119
[72]
L.R. Gagnon, C. Sadasivan, H. Yogasundaram, et al.
Review of hydroxychloroquine cardiotoxicity: lessons from the COVID-19 pandemic.
Curr Heart Fail Rep, 19 (2022), pp. 458-466
[73]
P.E. Lazzerini, P.L. Capecchi, F. Guideri, et al.
Connective tissue diseases and cardiac rhythm disorders: an overview.
Autoimmun Rev, 5 (2006), pp. 306-313
[74]
E. Arbelo, A. Protonotarios, J.R. Gimeno, et al.
2023 ESC Guidelines for the management of cardiomyopathies.
Eur Heart J, 44 (2023), pp. 3503-3626

These authors share co-authorship.

Copyright © 2025. Sociedad Española de Cardiología
Descargar PDF
Idiomas
REC: CardioClinics
Opciones de artículo
Herramientas